Latest Insider Transactions at Cytokinetics Inc (CYTK)
This section provides a real-time view of insider transactions for Cytokinetics Inc (CYTK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CYTOKINETICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CYTOKINETICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.21%
|
$70,000
$7.96 P/Share
|
|
Mar 02
2022
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+43.29%
|
-
|
|
Mar 02
2022
|
Robert I Blum President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+16.41%
|
-
|
|
Mar 02
2022
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,866
-4.36%
|
$587,042
$37.63 P/Share
|
|
Mar 02
2022
|
David Cragg Chief HR & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+11.2%
|
-
|
|
Mar 02
2022
|
David Cragg Chief HR & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,458
-2.43%
|
$127,946
$37.63 P/Share
|
|
Mar 02
2022
|
Ching Jaw SVP Finance & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+21.59%
|
-
|
|
Mar 02
2022
|
Ching Jaw SVP Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,458
-6.17%
|
$127,946
$37.63 P/Share
|
|
Mar 02
2022
|
Fady Ibraham Malik EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+14.42%
|
-
|
|
Mar 02
2022
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
5,004
-3.27%
|
$185,148
$37.63 P/Share
|
|
Mar 02
2022
|
Mark A Schlossberg SVP - Legal & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+21.64%
|
-
|
|
Mar 02
2022
|
Mark A Schlossberg SVP - Legal & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,457
-6.19%
|
$127,909
$37.63 P/Share
|
|
Mar 02
2022
|
Robert Wong VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+18.36%
|
-
|
|
Mar 02
2022
|
Robert Wong VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,447
-5.3%
|
$53,539
$37.63 P/Share
|
|
Mar 02
2022
|
Santo J Costa Director |
SELL
Open market or private sale
|
Direct |
10,000
-66.67%
|
$370,000
$37.35 P/Share
|
|
Mar 02
2022
|
Santo J Costa Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+40.0%
|
$100,000
$10.68 P/Share
|
|
Mar 01
2022
|
John T Henderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,166
+18.73%
|
$20,830
$5.46 P/Share
|
|
Feb 28
2022
|
Robert I Blum President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,329
-3.02%
|
$396,515
$35.32 P/Share
|
|
Feb 28
2022
|
David Cragg Chief HR & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,071
-1.44%
|
$72,485
$35.32 P/Share
|
|
Feb 28
2022
|
Ching Jaw SVP Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,074
-3.57%
|
$72,590
$35.32 P/Share
|
|
Feb 28
2022
|
Fady Ibraham Malik EVP Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
3,458
-2.21%
|
$121,030
$35.32 P/Share
|
|
Feb 16
2022
|
Robert I Blum President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
14,474
+1.91%
|
-
|
|
Feb 16
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.7%
|
$360,000
$36.5 P/Share
|
|
Feb 16
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.63%
|
$70,000
$7.96 P/Share
|
|
Feb 16
2022
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,044
+35.99%
|
-
|
|
Feb 16
2022
|
David Cragg Chief HR & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,008
+1.72%
|
-
|
|
Feb 16
2022
|
Ching Jaw SVP Finance & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
5,022
+4.22%
|
-
|
|
Feb 16
2022
|
Fady Ibraham Malik EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
7,148
+2.26%
|
-
|
|
Feb 16
2022
|
Mark A Schlossberg SVP - Legal & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
5,025
+4.39%
|
-
|
|
Feb 16
2022
|
Robert Wong VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,987
+3.57%
|
-
|
|
Feb 07
2022
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.7%
|
$330,000
$33.86 P/Share
|
|
Feb 07
2022
|
Robert I Blum President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.63%
|
$70,000
$7.96 P/Share
|
|
Jan 03
2022
|
Muna Bhanji Director |
BUY
Grant, award, or other acquisition
|
Direct |
244
+4.45%
|
$11,224
$46.0 P/Share
|
|
Jan 03
2022
|
Robert Califf Director |
BUY
Grant, award, or other acquisition
|
Direct |
122
+1.99%
|
$5,612
$46.0 P/Share
|
|
Jan 03
2022
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
244
+1.78%
|
$11,224
$46.0 P/Share
|
|
Jan 03
2022
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
244
+3.36%
|
$11,224
$46.0 P/Share
|
|
Jan 03
2022
|
Sandford D Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
122
+1.74%
|
$5,612
$46.0 P/Share
|
|
Jan 03
2022
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
122
+1.74%
|
$5,612
$46.0 P/Share
|
|
Jan 03
2022
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
122
+1.99%
|
$5,612
$46.0 P/Share
|
|
Dec 27
2021
|
Sandford D Smith Director |
SELL
Open market or private sale
|
Direct |
28,290
-50.24%
|
$1,273,050
$45.79 P/Share
|
|
Dec 27
2021
|
Sandford D Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
28,290
+32.61%
|
$565,800
$20.45 P/Share
|
|
Dec 27
2021
|
Wendall Wierenga Director |
SELL
Open market or private sale
|
Direct |
4,166
-38.11%
|
$183,304
$44.37 P/Share
|
|
Dec 27
2021
|
Wendall Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,166
+27.59%
|
$20,830
$5.46 P/Share
|
|
Dec 23
2021
|
Edward M. Md Kaye Director |
SELL
Open market or private sale
|
Direct |
15,000
-68.92%
|
$675,000
$45.0 P/Share
|
|
Dec 23
2021
|
Edward M. Md Kaye Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+40.8%
|
$105,000
$7.61 P/Share
|
|
Dec 09
2021
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
29,166
-8.67%
|
$1,049,976
$36.49 P/Share
|
|
Dec 09
2021
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
29,166
+7.82%
|
$174,996
$6.3 P/Share
|
|
Nov 19
2021
|
Sandford D Smith Director |
SELL
Open market or private sale
|
Direct |
29,032
-51.52%
|
$1,190,312
$41.21 P/Share
|
|
Nov 19
2021
|
Sandford D Smith Director |
BUY
Exercise of conversion of derivative security
|
Direct |
29,032
+33.26%
|
$348,384
$12.03 P/Share
|
|
Nov 12
2021
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
4,143
-1.14%
|
$161,577
$39.63 P/Share
|